


**Moksha Manish Shah<sup>1,2</sup>, Hannelore Bodocian<sup>1,3</sup>, Roland Zauner<sup>3</sup>, Mila Sajinovic<sup>1</sup>, Tim Mann<sup>1</sup>, Kieran Scott<sup>1</sup>, Paul De Souza<sup>1,2</sup>, Verena Wally<sup>3</sup>, Albert S. Mellick<sup>1,2</sup>**  
<sup>1</sup>Ingham Institute for Applied Medical Research, Medicine, University of New South Wales, Liverpool NSW, Australia. <sup>2</sup>Medicine, University of Wollongong, Wollongong NSW, Australia; <sup>3</sup>EB House Austria, University Hospital of the Paracelsus Medical University, Salzburg, Austria.


**Introduction.** Squamous cell carcinoma (SCC) is the second most common form of skin cancer, and the most common form of nonmelanoma skin cancer (NMSC). When caught early, most SCCs are curable. However, certain sub-types, such as those derived from patients with recessive dystrophic epidermolysis (RDEB), are more problematic [1]. In addition to being difficult to diagnose, SCCs from RDEB patients tend to be significantly more aggressive than SCCs identified in an otherwise healthy population. Because most cancers are treatable if detected early there is a great need to shorten the time between diagnosis and treatment. However, current methods, which involve skin biopsies, do not encourage regular screening. In EB patients such screening is especially problematic given that this cohort already has significant problems with wound healing. Consequently, there is a great need to develop less traumatic methods for diagnosing malignant RDEB SCCs. Recent work (currently in review), conducted as part of an international collaboration between the Mellick Laboratory (Ingham Institute for Applied Medical Research), and the Wally Laboratory (EB House) describes the identification of a small RNA (miR-10b) that may drive malignancy in both SCCs and RDEB SCCs (Wimmer *et al.* In review). As part of this larger study, we have continued to investigate the role of miR-10b as a maker of disseminated disease. By adapting methods the 'liquid' (or blood) biopsy we have established the feasibility of identifying miR-10b<sup>+</sup> SCCs and RDEB-SCCs from a blood biopsy using filtration based circulating tumour cell (CTC) isolation. In future we hope to adapt this methods for the regularly and effective screening of disseminated disease in RDEB.

**Approach & Results.** Several methods have been developed to analyse the presence of CTCs in the blood of cancer patients [2]. The most notable of these protocols include the CellSearch<sup>®</sup> methodology, which utilises epithelial cell adhesion molecule (EpCam) and Cytokeratin-with CD45 as an exclusion marker to extract and identify CTCs from a blood biopsy (Fig. 1) [3]. However, in recent years, marker based CTC analysis has been questioned, as the veracity of common marker combinations to label disseminated cancer cells has come into question. This is of particular importance to RDEB patients, because of the differential expression of cytokeratin in SCCs. MiR-10b expression was previously determined to be a hallmark of aggressive SCCs and RDEB-SCCs (Fig. 2). Consequently, given that the Mellick laboratory had already established expertise in CTC analysis we determined to begin optimisation of a filtration-based (size-exclusion) protocol (ScreenCell<sup>®</sup>) [4] to isolate and detect miR-10b<sup>+</sup> RDEB-SCCs. Filtration based protocols provide an objective means of isolating CTCs that is not dependent on any particular set of markers, and therefore can be adapted on to a particular pathology.


To first determine if we could distinguish miR-10b<sup>+</sup> RDEB-SCCs from other blood cells we examined primary cancer cells mixed with blood cells and 'cytospun' onto slides. We then applied the previously developed combined *in situ* hybridisation (ISH) and immunohistochemical approach (IHC), previously developed in the Mellick laboratory (Fig. 3) [3]. Given that we could distinguish both keratinocytes and SCCs from blood cells, we then proceeded to optimise the protocol for use in analysis of CTCs isolated from the blood using filtration (Fig. 4). Not time only did we find that we could use the ISH-IHC protocol effectively, but for the first time we have been able to show that RDEB-SCCs could be isolated by size exclusion from blood.




**Figure 1** A, Digoxigenin (DIG)-labelled anti-miR-10b locked nucleic acid (LNA) probes detected with **Fluorescein isothiocyanate (FITC)-labelled** anti-DIG antibody, which allows for visualisation of miR expression following CTC isolation using the CellSearch/CellTracks Analyzer<sup>®</sup>. CTCs can then be identified as either **miR-10b<sup>+</sup>, Cytokeratin (CK)<sup>+</sup>, CD45<sup>+</sup>**; and/or **miR-10b<sup>-</sup>, CK<sup>+</sup>, CD45<sup>+</sup>** (B). Shown results of analysis of blood from prostate, breast cancer colon cancer patients. For a detailed method see Gasch *et al. Sci Rep.* 2015 [3].



**Figure 2** A, Shown, higher levels of miR-10b in RDEB-SCCs/SCCs, compared with RDEB and control keratinocytes (KCs), by Q-PCR. B, FITC-DIG miR-10b probes used to semi-quantitate expression in RDEB-SCCs. Scale 50  $\mu$ m. C, Tissue sections showing **CK** and **miR-10b** expression in tissue from an RDEB-SCC, and RDEB-SCC lymph node metastasis. Scale 100  $\mu$ m. Wimmer *et al.* in review.



**Figure 3** A, Schematic, filter/funnel for cyto-spinning cells onto slides. B (20 x resolution) & C (60 x resolution). Immunofluorescent microscopy of cytospun RDEB-SCCs, stained with **miR-10b** and neg. (scrambled) control. Shown, **miR-10b<sup>+</sup> cytokeratin (CK)<sup>+</sup> CD45<sup>+</sup>** RDEB-SCCs as well as hematopoietic **miR-10b<sup>+</sup> CD45<sup>+</sup>** hematopoietic cells.



**Figure 4** A, Schematic of ScreenCell<sup>®</sup> protocol. Cells were spiked into blood and captured by filtration. B, Immunofluorescent microscopy of the filter. Note the 'fried egg' appearance of **CK<sup>+</sup>, miR-10b<sup>+</sup> CD45<sup>+</sup>** cancer cells (white arrows) on the membrane. Also shown, **CK<sup>+</sup>, miR-10b<sup>+</sup>, CD45<sup>+</sup>** hematopoietic cells (red arrows). C, Orthotopic projection of RDEB-SCC (Z-stack), showing vertical and horizontal projections through the membrane.

**Conclusions.** Recent advances have significantly improved life expectancy and quality of life for patients with RDEB. Patients now live longer. However, at the same time screening and treatment of RDEB SCCs has not significantly improved. For all intent and purpose by the time SCCs are diagnosed in RDEB they have already spread and are difficult to treat. There is a desperate need for more efficient diagnostic methods that can accurately identify cancers that have spread. Unfortunately current liquid biopsy based analysis developed for epithelial cancers may not be appropriate for SCCs derived from RDEB patients. The use of unbiased size exclusion filtration protocols and by incorporating more effective markers of malignancy we hope to provide a tool that can be used to identify signs of cancer spread. While more work needs to be done, it is hoped that by identifying a malignant cancer earlier, appropriate life extending treatments can be employed. In addition the use of filters that can be dried and stored and transported prior to analysis, as well as simple protocol for capturing cancer cells will greatly expand the use and utility of liquid biopsy based protocols in the diagnosis of RDEB-linked SCCs.

**Acknowledgements.** This work was funded by grants provided by DEBRA Australia. We would also like to acknowledge the support of members of the Ingham Institute for Applied Medical Research, including Mr Paul Baek, Mr Grigori Kaplan, as well as Dr Tzipi Cohen Hyams and A/Prof Murray Killingsworth (Imaging Facility), members of the Medical Oncology Unit, including A/Prof Kevin Spring, and A/Prof Kieran Scott.

## References

- Kim M, Li M, Intong-Wheeler LRA, Tran K, Marucci D, Murrell DF. (2018) Epidemiology and Outcome of Squamous Cell Carcinoma in EB in Australia and New Zealand. *Acta Derm Venereol.* 98:70-6.
- Kulasinghe A, Kenny L, Perry C, Thiery JP, Jovanovic L, Vela I, Nelson C, Punyadeera C. (2016) Impact of label-free technologies in head and neck cancer circulating tumour cells. *Oncotarget.* 7:1223-34.
- Gasch C, Plummer PN, Jovanovic L, McInnes LM, Wescott D, Saunders CM, Schneeweiss A, Wallwiener M, Nelson C, Spring KJ, Riethdorf S, Thompson EW, Pantel K, Mellick AS. (2015) Heterogeneity of miR-10b expression in circulating tumor cells. *Sci Rep.* 5:15980.
- Desitter I, Guerrouahen BS, Benali-Furet N, Wechsler J, Jänne PA, Kuang Y, Yanagita M, Wang L, Berkowitz JA, Distel RJ, Cayre YE. (2011) A new device for rapid isolation by size and characterization of rare circulating tumor cells. *Anticancer Res.* 31:427-41.